Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07167914
PHASE1

A Study to Assess Safety, Tolerability and Pharmacokinetics of Transdermal SFG-02 in Healthy Participants

Sponsor: Juro Sciences Inc.

View on ClinicalTrials.gov

Summary

This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of a novel transdermal formulation of SFG-02 following single and repeated applications in Japanese and White healthy adult participants.

Official title: A Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Transdermal Doses of SFG-02 in Japanese and White Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2025-09

Completion Date

2026-04

Last Updated

2025-09-11

Healthy Volunteers

Yes

Interventions

DRUG

SFG-02

Transdermal Formulation (SFG-02)

DRUG

Placebo

Transdermal Formulation (Placebo)

Locations (1)

Sumida Hospital

Tokyo, Japan